ckd glp-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Potential kidney-protective and other effects

An extended 12-month care plan for better treatment continuity, designed to support appetite regulation and manage sustainable weight loss

A recent cohort study has illuminated significant disparities in the fulfillment of prescriptions for glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of medications pivotal in managing

Regardless of drugs, lifestyle matters: physical activity, healthy diet, sleep, social connection, cognitive engagementall are evidence-based pillars of brain health

Future research should prioritize elucidating the molecular mechanisms behind the antitumor effects, refining individualized treatment strategies, investigating early tumor prevention applications, assessing potential benefits for non-diabetic populations, advancing the development of novel therapies, establishing robust safety monitoring frameworks, and building precision medicine decision-making platforms

Diabetic patients prescribed tirzepatide, semaglutide, dulaglutide, and exenatide are less likely to be diagnosed with depression after starting the medication compared to those not on a glucagon-like peptide-1 receptor agonist (GLP-1) medication.

No commitment.